Overview

Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The primary objectives of the study to evaluate the effects of two doses of nalbuphine HCl ER tablets on the change from baseline in the worst itch Numerical Rating Scale (NRS) in hemodialysis patients with moderate to severe uremic pruritus and to evaluate the safety and tolerability in the study population.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Trevi Therapeutics
Treatments:
Nalbuphine